Abstract
Insulin is a double-chain (designated A and B chain respectively) protein hormone containing three disulfides, while insulin is synthesized in vivo as a single-chain precursor and folded well before being released from B-cells. Although the structure and function of insulin have been well characterized, the progress in oxidative folding pathway studies of insulin has been very slow, mainly due to the difficulties brought about by its disulfide-linked double-chain structure. To overcome these difficulties, we recently studied the in vitro oxidative folding process of two single-chain insulins: porcine insulin precursor (PIP) and human proinsulin (HPI). Based on the analysis of the intermediates captured during folding process, the folding pathways have been proposed for PIP and HPI separately. Similarities between the two folding pathways disclose some common principles that govern the insulin folding process. The following unfolding studies of PIP and HPI further indicate that C-peptide might also function during the folding of proinsulin. Here, we gave a brief review on in vitro folding/unfolding process of insulin and single-chain insulin. The implication of these studies on protein folding has also been discussed.
Keywords: Insulin, Single-chain insulin, Folding, Unfolding, Disulfide
Protein & Peptide Letters
Title: In Vitro Folding/Unfolding of Insulin/Single-Chain Insulin
Volume: 13 Issue: 5
Author(s): Zhi-Song Qiao, Zhan-Yun Guo and You-Min Feng
Affiliation:
Keywords: Insulin, Single-chain insulin, Folding, Unfolding, Disulfide
Abstract: Insulin is a double-chain (designated A and B chain respectively) protein hormone containing three disulfides, while insulin is synthesized in vivo as a single-chain precursor and folded well before being released from B-cells. Although the structure and function of insulin have been well characterized, the progress in oxidative folding pathway studies of insulin has been very slow, mainly due to the difficulties brought about by its disulfide-linked double-chain structure. To overcome these difficulties, we recently studied the in vitro oxidative folding process of two single-chain insulins: porcine insulin precursor (PIP) and human proinsulin (HPI). Based on the analysis of the intermediates captured during folding process, the folding pathways have been proposed for PIP and HPI separately. Similarities between the two folding pathways disclose some common principles that govern the insulin folding process. The following unfolding studies of PIP and HPI further indicate that C-peptide might also function during the folding of proinsulin. Here, we gave a brief review on in vitro folding/unfolding process of insulin and single-chain insulin. The implication of these studies on protein folding has also been discussed.
Export Options
About this article
Cite this article as:
Qiao Zhi-Song, Guo Zhan-Yun and Feng You-Min, In Vitro Folding/Unfolding of Insulin/Single-Chain Insulin, Protein & Peptide Letters 2006; 13 (5) . https://dx.doi.org/10.2174/092986606776819583
DOI https://dx.doi.org/10.2174/092986606776819583 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member:
Current Diabetes Reviews In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease
Current Medicinal Chemistry Computational Advances in Chronic Diseases Diagnostics and Therapy - II
Current Drug Targets The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives
Current Drug Metabolism Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Targeting the Histidine Pathway in Mycobacterium tuberculosis
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery A Comparison of Biomarkers in the Assessment of Glycemic Control in Diabetes: Reviewing the Evidence
Current Diabetes Reviews A Renewable Source as a Functional Food: Chia Seed
Current Nutrition & Food Science Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design Pre-clinical Validation of Mito-targeted Nano-engineered Flavonoids Isolated From Selaginella bryopteris (Sanjeevani) As A Novel Cancer Prevention Strategy
Anti-Cancer Agents in Medicinal Chemistry Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Anti-Inflammatory, Gastrointestinal and Hepatoprotective Effects of Ocimum sanctum Linn: An Ancient Remedy with New Application
Inflammation & Allergy - Drug Targets (Discontinued) Docking and Molecular Dynamics Simulations of Peroxisome Proliferator Activated Receptors Interacting with Pan Agonist Sodelglitazar
Protein & Peptide Letters Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Advances in Sub-Micron Particle Based Aerosol Strategies for Efficient Systemic Delivery of Therapeutic Agents
Current Pharmaceutical Design